Laminin-332 and type IV collagen expression in oral lichen planus and oral lichenoid lesion: potential use as markers for malignant transformation

• Grant number: 20/10868-1
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: December 01, 2020
• End date: November 30, 2021
• Field of knowledge: Health Sciences - Dentistry
• Principal Investigator: Ana Carolina Fragoso Motta
• Grantee: Mayara Sayuri Kamimura Akama
• Host Institution: Faculdade de Odontologia de Ribeirão Preto (FORP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

Oral lichen planus (OLP) is a chronic inflammatory disease, which mainly affects women, with frequency ranging from 0.1% to 4% in the general population, and, although controversial, it is considered a potentially malignant disorder. Several markers have been proposed as indicators of malignant transformation, with the possibility of contributing to clarifying the issue of malignant transformation of OLP, including laminin-332 and type IV collagen. This project aims to determine the expression of laminin-332 and type IV collagen in samples of oral mucosa from patients diagnosed with OLP and oral lichenoid lesion (OLL), through immunohistochemical study. The diagnosis of OLP and OLL will follow the criteria of van der Meij & van der Waal, 2003. Samples of patients in care at three higher education institutions will be included: School of Dentistry of Ribeirão Preto - USP, Medical School of Ribeirão Preto - USP, School of Dentistry - USP and University from the State of Amazonas, from November 2013 to February 2020. Information on age, sex, race, clinical form, location, time of evolution, association with emotional factors, systemic comorbidities, use of drugs, smoking and alcohol comsuption will be investigated. Samples of epithelial dysplasia (ED), oral squamous cell carcinoma (OSCC) and fibrous hyperplasia (FH) will be used for morphological and immunohistochemical comparisons. This project is expected to identify aspects that may interfere in the evolution of the OLP. This study was approved by the FORP/USP Research Ethics Committee (CAAE#: 33703114.8.0000.5419) and all patients must provide free and informed consent.